We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Saturating Cancerous Livers with Chemotherapy may be Beneficial and could Limit Toxic Side Effects
News

Saturating Cancerous Livers with Chemotherapy may be Beneficial and could Limit Toxic Side Effects

Saturating Cancerous Livers with Chemotherapy may be Beneficial and could Limit Toxic Side Effects
News

Saturating Cancerous Livers with Chemotherapy may be Beneficial and could Limit Toxic Side Effects

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Saturating Cancerous Livers with Chemotherapy may be Beneficial and could Limit Toxic Side Effects"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Minimally invasive chemosaturation delivers high doses of chemotherapy into the liver to more effectively battle tumors while limiting toxicity to the rest of the body.

“The minimally invasive method isolates the drug so it is contained within the liver, where tumors receive up to 100 times the dose they would get through systemic chemotherapy”. Patients with melanoma that had spread to the liver who underwent percutaneous hepatic perfusion (PHP) survived four times longer before the disease progressed, compared to patients who did not receive the treatment, according to results of the multicenter randomized study.
The study included 93 patients: 44 received PHP and 49 received standard treatment (typically systemic chemotherapy). In the latter group, 27 began receiving PHP when their disease progressed. Patients in the PHP group averaged 186 days before the disease progressed compared to 46 days for patients who did not receive PHP. Those in the PHP group benefitted from an average of 245 days without progression of cancer in the liver compared to 49 days for those in the standard treatment group, a five-fold increase for the PHP group.

“The minimally invasive method isolates the drug so it is contained within the liver, where tumors receive up to 100 times the dose they would get through systemic chemotherapy,” said investigator Charles Nutting, DO, FSIR, an interventional radiologist at Swedish Medical Center, Denver, Co. “There are very limited therapeutic options for these patients. This minimally invasive therapy technology could eventually be used to treat other liver cancers when options are limited.”
PHP involves delivering chemotherapy via an arterial catheter threaded through the blood vessels to the liver. Two balloons are inflated in the vena cava, above and below the liver to isolate the chemotherapy. This chemotherapy-saturated blood is then cleansed by a series of filters and returned to the body. PHP allows the entire liver to be treated, which is beneficial in patients with more than one tumor.

Advertisement